Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC

Phase II Trial To Initiate In Q4; Data In 2024

Executive Summary

A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.

You may also be interested in...



Amgen’s Lumakras Efficacy Confirmed In Phase III, But Not As Strong As Phase II

Lumakras data at ESMO in KRAS G12C-mutated lung cancer bested docetaxel on PFS, and largely on safety. OS was better for chemotherapy, but the trial was not powered for statistical significance on OS.

Mirati’s Adagrasib Appears To Maintain CRC Edge In KRAS Race

The company is reporting strong ORR, durability and PFS at ESMO in heavily pretreated colorectal cancer, an indication where Amgen’s Lumakras has struggled.

AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel